Document is current
Any future updates will be listed below
-
Authors
De Stefano, Lisa A.
Kim, Hyeonseok
Erickson, Craig A.
Pedapati, Ernest V.
Dominick, Kelli C.
Shaffer, Rebecca
Wink, Logan K.
Schmitt, Lauren M.
Miyakoshi, Makoto
-
Funding
Funding for this research was provided by:
FRAXA Research Foundation
Ohio Third Frontier Fund
Cincinnati Children’s Research Foundation
- License Information
-
More Information
Article History
Received: 15 November 2025
Accepted: 11 March 2026
First Online: 1 April 2026
Competing interests
: This study was funded by the Cincinnati Children’s Hospital Research Foundation, the State of Ohio’s Ohio Development Services Agency, and the FRAXA Research Foundation. Drug and matching placebo were provided by Baergic Bio, Inc. CAE is a co-inventor on a patent describing the method of use of BAER-101 in fragile X syndrome with the patent held by the Cincinnati Children’s Hospital Research Foundation. The authors otherwise have no conflicts or financial agreements in direct conflict with any information reported in this manuscript.
